Our results show that different JAK/STAT pathway mutations induce PIM1 overexpression, postulating PIM1 activity as a relevant event for the leukemogenic effects mediated by the JAK/STAT pathway mutations identified in T-ALL/LBL, as well as a potential therapeutic target in this malignancy. The gene discussed is PIM1; the disease is acute lymphoblastic leukemia.